Conditions: Pharmacokinetics Cytochrome P-450 CYP2D6 CYP3A4 Protein, Human
Keywords: Pharmacokinetic safety and tolerability genetic testing CYP 2D6 and CYP 3A4
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 38
Healthy volunteers: yes

Brief summary:
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Aripiprazole when coadministered to healthy adult subjects.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Aripiprazole intervention 2: Aripiprazole + desvenlafaxine succinate sustained release
Intervention descriptions: intervention 1: Period 1-Aripiprazole 5mg on study day 1. intervention 2: Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.

Protocol document: